Sugi Predict

Sugi Predict / Compounds / SCHEMBL10260675

SCHEMBL10260675

SCHEMBL10260675

COc1ccc(NC(=O)[C@@H](CCCNC(=N)N)NC(=O)c2cc(NC(=O)[C@@H](CCCNC(=N)N)NC(=O)c3cc(NC(=O)[C@@H](CCCNC(=N)N)NC(=O)c4cc(NC(C)=O)ccc4OC)ccc3OC)ccc2OC)cc1C(=O)NCCN

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ MMP2 P08253 2/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ KCNB1 Q14721 1/20 0.36
▸ MCHR1 Q99705 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ PYGL P06737 1/20 0.35
▸ NPY1R P25929 1/20 0.35
▸ NPY4R P50391 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21372067 0.97 ALDH1A1 (0.39) ALDH1A1TSHRMMP2NPC1RAB9A
SCHEMBL19486000 0.95 ALDH1A1 (0.36) ALDH1A1TSHRMMP2NPC1RAB9A
SCHEMBL10263115 0.95 ALDH1A1 (0.38) ALDH1A1TSHRMMP2NPC1RAB9A
SCHEMBL10262709 0.93 MMP2 (0.37) TSHRMMP2CA1CA2KCNB1
SCHEMBL10262700 0.92 NPY4R (0.41) TSHRMMP2NPY1RNPY4R
SCHEMBL10262445 0.92 NPY4R (0.38) TSHRMMP2KCNB1MCHR1NPY1R
SCHEMBL19445176 0.92 LMNA (0.41) ALDH1A1TSHRMMP2NPC1RAB9A
SCHEMBL10262220 0.92 ALDH1A1 (0.41) ALDH1A1TSHRMMP2CA1CA2
SCHEMBL12515508 0.92 ALDH1A1 (0.41) ALDH1A1TSHRMMP2CA1CA2
SCHEMBL15277753 0.92 ALDH1A1 (0.41) ALDH1A1TSHRMMP2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10603294-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2020-03-31 — — US disclosed
US-20190282521-A1 Compounds For Use In Treatment Of Mucositis POLYMEDIX, INC. 2019-09-19 — — US disclosed
US-10206894-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2019-02-19 — — US disclosed
US-20180064664-A1 Compounds For Use In Treatment of Mucositis POLYMEDIX, INC. 2018-03-08 — — US disclosed
US-9795575-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2017-10-24 — — US disclosed
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis INNOVATION PHARMACEUTICALS INC. 2017-08-10 — — US disclosed
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis INNOVATION PHARMACEUTICALS INC. 2017-08-10 — — US disclosed
US-9457027-B2 Compounds for use in treatment of mucostis CELLCEUTIX CORPORATION (US) 2016-10-04 — — US disclosed
US-20160213668-A1 Compounds for use in Treatment of Mucostis INNOVATION PHARMACEUTICALS INC. 2016-07-28 — — US disclosed
US-9155738-B2 Compounds for use in treatment of mucostitis CELLCEUTIX CORPORATION (US) 2015-10-13 — — US disclosed
US-20140364364-A1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS INNOVATION PHARMACEUTICALS INC. 2014-12-11 — — US disclosed
US-8802683-B2 Compounds for use in treatment of mucositis CELLCEUTIX CORPORATION (US) 2014-08-12 — — US disclosed
US-20120295922-A1 Compounds For Use In Treatment Of Mucositis POLYMEDIX, INC. (US) 2012-11-22 — — US disclosed
US-20120258141-A9 Methods Of Immune Modulation UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-10-11 — — US disclosed
US-20120039945-A1 Methods Of Immune Modulation UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-02-16 — — US disclosed
US-20110178104-A1 Anti-Heparin Compounds POLYMEDIX INC. (US) 2011-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 ALDH1A1 1289/4885TSHR 4275/4885MMP2 367/4885
US-10603294-B2 Compounds for use in treatment of mucositis MUC1, FUT6, MMP8 ALDH1A1 1289/4885TSHR 4275/4885MMP2 367/4885
US-20140364364-A1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS MUC1, FUT6, MMP8 ALDH1A1 1289/4885TSHR 4275/4885MMP2 367/4885
US-20120295922-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 ALDH1A1 1289/4885TSHR 4275/4885MMP2 367/4885
US-20120258141-A9 Methods Of Immune Modulation IFNG, CD14, TLR3 ALDH1A1 2581/4885TSHR 3953/4885MMP2 3191/4885
US-20120039945-A1 Methods Of Immune Modulation IFNG, CD14, TLR3 ALDH1A1 2581/4885TSHR 3953/4885MMP2 3191/4885
US-10206894-B2 Compounds for use in treatment of mucositis MUC1, FUT6, SI ALDH1A1 899/4885TSHR 4769/4885MMP2 595/4885
US-20110178104-A1 Anti-Heparin Compounds SERPINC1, CFH, SERPINH1 ALDH1A1 3248/4885TSHR 2112/4885MMP2 174/4885
US-20190282521-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 ALDH1A1 1289/4885TSHR 4275/4885MMP2 367/4885
US-20180064664-A1 Compounds For Use In Treatment of Mucositis MUC1, FUT6, SI ALDH1A1 899/4885TSHR 4769/4885MMP2 595/4885
US-20160213668-A1 Compounds for use in Treatment of Mucostis MUC1, SOST, ALG1 ALDH1A1 1127/4885TSHR 3166/4885MMP2 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback